ROS1 and non-small cell lung carcinoma: In our real-world study conducted in South Korea, the incidence of brain/CNS metastases at the baseline in ROS1-rearranged NSCLC patients receiving crizotinib was 32.5%, which is higher than in most other studies (3.2–23.1%) [25,28,29,38].